Is there a risk of Clostridioides difficile infection with Dexilant (dexlansoprazole) 60 mg, and how can I minimize that risk?

Risk of Clostridioides difficile Infection with Dexilant 60 mg

Yes, Dexilant (dexlansoprazole) 60 mg carries an increased risk of C. difficile infection, and you should use the lowest effective dose for the shortest duration necessary while avoiding unnecessary antibiotics. 1

Understanding the Risk

The FDA label for dexlansoprazole explicitly warns that PPI therapy may be associated with an increased risk of Clostridioides difficile-associated diarrhea, especially in hospitalized patients. 1 However, the strength and clinical significance of this association remains controversial in the medical literature.

Evidence for the Association

• Epidemiologic studies consistently show an association between PPI use and CDI, with pooled relative risks around 1.26 (95% CI 1.12-1.39). 2

• Dose-response relationship: Recent meta-analysis data suggest a linear trend with approximately 2% increased risk per day of PPI therapy and 5% increased risk per 10 mg defined daily dose. 3

• Recurrence risk: In healthcare-associated CDI, continuous PPI use was independently associated with a 50% increased risk for recurrence—actually higher than the 30% increased risk from antibiotic re-exposure. 4

• Mechanism: PPIs reduce gastric acid, which normally provides a protective barrier against ingested C. difficile spores, and long-term use decreases lower gastrointestinal microbial diversity. 4

The Controversy

Important caveat: The IDSA/SHEA guidelines note that well-controlled studies suggest this association may result from confounding factors—underlying severity of illness, non-CDI diarrhea, and duration of hospital stay—rather than a direct causal effect. 4 PPIs themselves can induce diarrhea, making patients more likely to be tested for CDI. 4

Despite this uncertainty, the IDSA/SHEA guidelines state that unnecessary PPIs should always be discontinued, though they provide no formal recommendation for stopping PPIs specifically as a CDI prevention measure due to insufficient evidence. 4

How to Minimize Your Risk

Primary Prevention Strategies

1. Optimize PPI Use

• Use the lowest effective dose and shortest duration appropriate for your condition. 1
• Regularly reassess whether you still need the PPI—many patients continue PPIs indefinitely without clear ongoing indication. 4
• The FDA label specifically recommends this approach for CDI risk reduction. 1

2. Avoid Unnecessary Antibiotics

• Minimize frequency, duration, and number of antibiotic agents, as this is the strongest modifiable risk factor for CDI. 4
• The risk of CDI is highest during antibiotic therapy and the first month after exposure, but remains elevated for up to 3 months after cessation. 2, 5
• Even single-dose surgical prophylaxis can increase CDI risk. 4, 5

3. Highest-Risk Antibiotics to Avoid When Possible

• Clindamycin (highest risk, OR 2.12-42). 6, 2
• Fluoroquinolones (OR 5.65-30.71). 2
• Third-generation cephalosporins (OR 3.2-5.3). 2
• Penicillins and β-lactamase inhibitor combinations. 2
• If antibiotics are necessary while on Dexilant, the combined risk is amplified—particularly with fewer antibiotic exposures where PPI effect is most pronounced. 7

4. Hand Hygiene

• Wash hands with soap and water rather than alcohol-based sanitizers, as alcohol does not kill C. difficile spores. 4
• This is especially important if you are hospitalized or visiting healthcare facilities. 4

Risk Factors That Increase Your Vulnerability

You are at higher risk if you have:

• Age >65 years. 4
• Recent hospitalization or long-term care facility exposure. 4
• Inflammatory bowel disease. 4
• Immunosuppression (HIV, chemotherapy, chronic steroids). 4
• Multiple comorbidities or low albumin. 4
• Recent or current antibiotic use (especially within the past 3 months). 2, 5

When to Seek Medical Attention

Consider CDI if you develop diarrhea that does not improve while taking or recently after taking Dexilant, especially if you have received antibiotics. 1 The FDA label specifically instructs that this diagnosis should be considered for persistent diarrhea. 1

Critical Clinical Pitfall to Avoid

Do not assume that a gap of weeks or months between antibiotic exposure and diarrhea onset excludes antibiotic-associated CDI. The risk window extends up to 3 months after antibiotic cessation, and PPI use during this period can act as an additional trigger. 2, 5 The combination of prior antibiotic exposure plus ongoing PPI creates cumulative risk. 2, 5

Probiotics: Insufficient Evidence

There are insufficient data to recommend probiotics for primary prevention of CDI outside of clinical trials. 4 While theoretically appealing, this strategy lacks strong evidence and should not be relied upon as a prevention method.